Posted by AGORACOM-JC
at 12:09 PM on Thursday, February 21st, 2019
CardioComm is a leading global provider of consumer heart monitoring
and ane electrocardiogram (aka “EKG”) solutions. Their products are
sold in over 20 countries and they’ve received numerous awards over the
years.
So what does that mean?
If you’ve ever had to have your heart checked out, you know the
experience involves going to a hospital / clinic and being hooked up to
machines that make you look like you’re plugged into the matrix. A
technician takes a bunch of readings and a doctor tries to come up with a
status of your heart’s condition.
PROBLEM 1: It is a terribly outdated system. You have to leave
work. The hospital / clinic has to buy & maintain a bunch of
machines. The process is very time consuming. The entire problem also
gets a lot worse if you don’t live near a major city with great
hospitals, doctors and equipment.
PROBLEM 2: WORSE of all, if your heart is playing nice that day and
isn’t showing signs of problems that have got your worried, you don’t
get a proper diagnosis and / or you may have to come back again.
SOLUTION? You guessed it >> CardioComm. Thanks to the
combination of your smartphone + an app and some tiny nodes to place on
your chest, your heart can be monitored at length during normal activity
to get you the best diagnosis possible. The results are shot up to the
cloud, where they are remotely analyzed by doctors / technicians that
can then speak to you directly, or get you into a hospital ASAP.
This is the simplified version. Now watch CEO Etienne Grima give you
the deep dive in a way that will actually have you on the edge of your
seat yearning for more.
If you love the transition of big existing things to digital, then
you are going to love what CardioComm does. Grab a cup of coffee and
watch this.
Posted by AGORACOM-JC
at 10:16 AM on Thursday, February 21st, 2019
Move is Part of Growing Sales, Marketing and Strategic Partnership Activities in the United States
confirms it has retained Whiteford, Taylor & Preston L.L.P. to assist in software licensing and intellectual property business matters on a go forward basis.
Toronto, Ontario–(February 21, 2019) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or the “Company“), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, confirms it has retained Whiteford, Taylor & Preston L.L.P. to assist in software licensing and intellectual property business matters on a go forward basis.
Whiteford, Taylor & Preston includes over 170 attorneys in
sixteen offices located in Delaware, the District of Columbia, Kentucky,
Maryland, Michigan, New York, Pennsylvania and Virginia, and is one of
the mid-Atlantic’s leading law firms.
As new opportunities develop in the US, the Company will be well
served with representation from a firm located in the United States with
experience in identifying, protecting, expanding and leveraging the
Company’s technologies and IP assets. Further, Whiteford, Taylor &
Preston meets the Company’s need for guidance from a firm with expertise
in working with a medical software company that does business in both
hospital and large institutional environments, as well as the consumer
health and wellness sectors.
To learn more about CardioComm’s products and for further updates
regarding software releases and new device integrations, please visit
the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.
CardioComm Solutions’ patented and proprietary technology is used in
products for recording, viewing, analyzing and storing
electrocardiograms for diagnosis and management of cardiac patients.
Products are sold worldwide through a combination of an external
distribution network and a North American-based sales team. CardioComm
Solutions has earned the ISO 13485:2016 certification, is HIPAA
compliant and holds clearances from the European Union (CE Mark), the
USA (FDA) and Canada (Health Canada).
This release may contain certain forward-looking statements and
forward-looking information with respect to the financial condition,
results of operations and business of CardioComm Solutions and certain
of the plans and objectives of CardioComm Solutions with respect to
these items. Such statements and information reflect management’s
current beliefs and are based on information currently available to
management. By their nature, forward-looking statements and
forward-looking information involve risk and uncertainty because they
relate to events and depend on circumstances that will occur in the
future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by
these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue
reliance on forward-looking statements and forward-looking information.
The Company does not assume any obligation to update the forward-looking
statements and forward-looking information contained in this release
other than as required by applicable laws, including without limitation,
Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 8:35 AM on Wednesday, February 13th, 2019
The Novel 12 Lead ECG Belt will be Marketed into the US Hospital and Telemed Markets
Entered into a device technology relationship for the co-marketing and US sales of a Smartphone connected 12 lead ECG wearable device
The announcement follows the successful integration and testing of the device with CardioComm’s GlobalCardio (“GC”) 12 FLEX remote ECG patient management platform and its hospital-based GEMS™ WIN software.
Toronto, Ontario–(February 13, 2019) – CardioComm Solutions, Inc.(TSXV: EKG) (“CardioComm” or the “Company“), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, confirms it has entered into a device technology relationship for the co-marketing and US sales of a Smartphone connected 12 lead ECG wearable device.
The announcement follows the successful integration and testing of the device with CardioComm’s GlobalCardio (“GC“)
12 FLEX remote ECG patient management platform and its hospital-based
GEMS™ WIN software. Joint sales efforts will be launched during the 2019
Healthcare Information and Management Systems Society (“HIMSS“)
Global Conference & Exhibition in Orlando this week. HIMSS is
expected to attract over 45,000 health information and technology
professionals, clinicians, executives and market suppliers from around
the world.
The device is a simple to use, 12 lead ECG belt that is placed around
the chest without the use of disposable supplies. The belt is intended
for in-home use under a physician’s prescription and can be placed
properly without the need for any medical training. Once the belt is in
place, ECGs are recorded and uploaded to a cloud service from where ECG
files are pulled into CardioComm’s software.
GC12 FLEX and GEMS™ WIN provide an FDA cleared, back-office solution
for centralized ECG data collection from remotely monitored patients.
Physicians and/or ECG reading services can access their data securely
for review and ECG reporting. GC12 FLEX also offers optional automated
ECG interpretation to ease the ECG review process. GC12 and GEMS WIN are
device agnostic solutions that offer healthcare professionals a
simplified, “one-software-for-all-ECG-devices” single platform solution.
CardioComm continues to seek out innovative hardware technologies
that will provide reliable ECG monitoring of people outside of a
hospital environments. The Company expects the 12 lead ECG belt will be
of interest to its current hospital and physician group customer base,
as well as to a growing number of remote and telemedicine patient
management providers that are looking for ways to add ECG monitoring to
their services. As part of the relationship the device manufacturer will
promote the use of the CardioComm software to its growing client list
looking to use 12 lead ECG monitoring within their operations.
To learn more about CardioComm’s products and for further updates
regarding software releases and new device integrations, please visit
the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.
CardioComm Solutions’ patented and proprietary technology is used in
products for recording, viewing, analyzing and storing
electrocardiograms for diagnosis and management of cardiac patients.
Products are sold worldwide through a combination of an external
distribution network and a North American-based sales team. CardioComm
Solutions has earned the ISO 13485:2016 certification, is HIPAA
compliant and holds clearances from the European Union (CE Mark), the
USA (FDA) and Canada (Health Canada).
This release may contain certain forward-looking statements and
forward-looking information with respect to the financial condition,
results of operations and business of CardioComm Solutions and certain
of the plans and objectives of CardioComm Solutions with respect to
these items. Such statements and information reflect management’s
current beliefs and are based on information currently available to
management. By their nature, forward-looking statements and
forward-looking information involve risk and uncertainty because they
relate to events and depend on circumstances that will occur in the
future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by
these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue
reliance on forward-looking statements and forward-looking information.
The Company does not assume any obligation to update the forward-looking
statements and forward-looking information contained in this release
other than as required by applicable laws, including without limitation,
Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Tags: ECG, tsx, tsx-v Posted in All Recent Posts, CardioComm Solutions, Featured | Comments Off on CardioComm $EKG.ca Solutions Now Offers a Smartphone Connected FDA Cleared 12 Lead ECG Belt Under a New Co-Marketing Agreement
